Analysis of NMDAR-PSD95-nNOS Signaling Pathway in Stroke

sNMDAR activation stimulates neuronal nitric oxide synthase (nNOS), which is coupled to the scaffolding protein postsynaptic densin 95 (PSD95). The binding of PSD95 to NMDAR and nNOS enhances Ca²⁺ influx, a hallmark of excitotoxicity in ischemic stroke. The interaction of the NMDA receptor NR2B subunit and PSD-95 has been demonstrated in an animal model of focal cerebral ischemic stroke by using a yeast two-hybrid screening technique. Signaling through the PSD95/nNOS complex is crucial for excitotoxicity in ischemic stroke and contributes to the neurotoxic effects of extra-synaptic NMDARs.

Fig. 1. The PSD95 brings nNOS into close proximity with the NMDAR channel pore. (Lai et al., 2014)

Our Services

Ace Therapeutics is a leading company specializing in stroke research and offers comprehensive services to analyze the NMDAR-PSD95-nNOS signaling pathway in stroke. We aim to help our clients develop potential stroke drugs to protect neuronal cells from excitotoxicity by inhibiting the NMDAR-PSD95-nNOS signaling pathway.

Our team of biologists and neuroscientists employs cutting-edge technologies to study NMDAR-PSD95-nNOS molecular interactions, downstream signaling pathways, and potential therapeutic targets associated with this pathway.

Downstream Signaling Pathway Analysis

The binding of the NMDAR/PSD-95/nNOS complex leads to phosphorylation activation through different mechanisms. At Ace Therapeutics, we use state-of-the-art techniques to study the phosphorylation events, calcium influx, and kinase-dependent pathways triggered by this complex.

• CaMKII-dependent mechanisms
• Src/Fyn kinase-dependent mechanism

Therapeutic Target Identification

Ace Therapeutics specializes in identifying novel therapeutic targets in the NMDAR-PSD95-nNOS signaling pathway. Through a combination of bioinformatics analysis, high-throughput screening, and functional assays, we help you develop key proteins, enzymes, or receptors that can be modulated to mitigate excitotoxicity and prevent neuronal damage in stroke.

With our expertise, state-of-the-art facilities, and collaborative approach, Ace Therapeutics is committed to helping clients explore new direction for the treatment of ischemic stroke by targeting NMDAR-PSD95-nNOS signaling pathway. If you are interested in our services, please do not hesitate to contact us!

1. Lai, T. W., et al. (2014). Excitotoxicity and stroke: identifying novel targets for neuroprotection. Progress in neurobiology, 115, 157-188.